Compare MGM Resorts International (MGM) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Pfizer Inc — how do they compare? MGM Resorts International trades at $46.49 (market cap $11.86B), while Pfizer Inc trades at $24.77 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 11.9× MGM Resorts International's market cap, and Pfizer Inc pays the higher dividend (6.95%). Which is the better fit depends on your goals.
| MGM | PFE | |
|---|---|---|
Market Cap | $11.86B | $141.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $28.56 |
52-Week Low | $30.72 | $23.29 |
Enterprise Value | $40.90B | $191.72B |
Dividend Yield | 0.03% | 6.95% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $46.55, up 0.91% today, amid ongoing acquisition talks with Barry Diller's People Inc. at $48.30 per share. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $17.54B in 2025, though net income margin compressed to 1.03%. Analyst consensus is evenly split between Buy and Hold, with a $48.93 price target suggesting modest upside from current levels.
MGM's outlook is clouded by acquisition uncertainty and declining profitability, offset by potential takeover premium and stable revenue. Key risks include execution on margin improvement, high debt levels, and macroeconomic sensitivity. The stock presents a speculative opportunity tied to deal completion, with fundamental challenges requiring careful monitoring.
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.
The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
